Regenerative Medicine Applied to Solid Organ Transplantation: Where Do We Stand?

被引:7
|
作者
Orlando, G. [1 ]
Di Cocco, P. [1 ]
D'Angelo, M. [1 ]
Clemente, K. [1 ]
Famulari, A. [1 ]
Pisani, F. [1 ]
机构
[1] Univ Aquila, I-67100 Laquila, Italy
关键词
D O I
10.1016/j.transproceed.2010.03.066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of regenerative medicine (RM) and Tissue Engineering (TE) is to create living functional tissues to repair or replace tissues or organ functions. This field holds the promise of regenerating damaged tissues and organs in the body. It has the potential to solve the problems of organ shortage and of toxicities deriving from life-long immunosuppression. In fact, cells in the regenerated organ would match those of the patient, from whom they would normally be derived. In the past decade, RM/TE has achieved striking results which are of interest to the transplant community. However, major roadblocks on the avenue to full success include the need for a deeper understanding of cell biology and of interactions with the extracellular matrix. We are presently not able to grow and expand cells indefinitely and safely in various scenarios where RM/TE may be indicated. The production of adequately vascularized scaffolds to optimize nutrients and oxygen delivery, assessment of the viability and function of the cells in the bioengineered construct, and the costs remain areas of scientific research.
引用
收藏
页码:1011 / 1013
页数:3
相关论文
共 50 条
  • [1] Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?
    Marin, Eros
    Cuturi, Maria Cristina
    Moreau, Aurelie
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] Tissue engineering and regenerative medicine -where do we stand?
    Horch, Raymund E.
    Kneser, Ulrich
    Polykandriotis, Elias
    Schmidt, Volker J.
    Sun, Jiaming
    Arkudas, Andreas
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 16 (06) : 1157 - 1165
  • [3] Immunoisolation: where regenerative medicine meets solid organ transplantation
    Pareta, Rajesh
    Sanders, Brian
    Babbar, Paurush
    Soker, Tom
    Booth, Christopher
    McQuilling, John
    Sivanandane, Sittadjody
    Stratta, Robert J.
    Orlando, Giuseppe
    Opara, Emmanuel C.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (07) : 685 - 692
  • [4] Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?
    Delville, Marianne
    Charreau, Beatrice
    Rabant, Marion
    Legendre, Christophe
    Anglicheau, Dany
    HUMAN IMMUNOLOGY, 2016, 77 (11) : 1055 - 1062
  • [5] Human pluripotent stem cells in regenerative medicine: where do we stand?
    Ha Thi Nguyen
    Jacobs, Kurt
    Spits, Claudia
    REPRODUCTION, 2018, 156 (05) : R143 - R153
  • [6] Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
    Trigo, Catarina M.
    Rodrigues, Joana S.
    Camoes, Sergio P.
    Sola, Susana
    Miranda, Joana P.
    JOURNAL OF ADVANCED RESEARCH, 2025, 70 : 103 - 124
  • [7] Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
    Ebert, Antje D.
    Diecke, Sebastian
    Chen, Ian Y.
    Wu, Joseph C.
    EMBO MOLECULAR MEDICINE, 2015, 7 (09) : 1090 - 1103
  • [8] Regenerative medicine in kidney disease: where we stand and where to go
    Borges, Fernanda T.
    Schor, Nestor
    PEDIATRIC NEPHROLOGY, 2018, 33 (09) : 1457 - 1465
  • [9] Regenerative medicine in kidney disease: where we stand and where to go
    Fernanda T. Borges
    Nestor Schor
    Pediatric Nephrology, 2018, 33 : 1457 - 1465
  • [10] Transplantation tolerance - where do we stand?
    Waldmann, H
    NATURE MEDICINE, 1999, 5 (11) : 1245 - 1248